Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders

Abstract

The present invention relates to the use of binding partners for 5-HT5 receptors for the treatment of neuropathological, in particular neurodegenerative and/or neuropsychiatric, disorders, which can occur, in particular, in cerebral ischemia, stroke, epilepsy and seizures in general, chronic schizophrenia, other psychotic disorders, dementia, in particular Alzheimer's dementia, demyelinizing disorders, in particular multiple sclerosis, and brain tumors. The invention also relates to processes for the identification and characterization of such binding partners, in particular in the form of screening processes.

1 - 10 . (canceled)  
     
     
         11 . A method of treating neuropsychiatric disorders, which comprises administering to a subject in need thereof an effective amount of at least one binding partner for a 5-HT5 receptor, the Ki value of the binding partner being less than 10 −7  M for binding thereof to the 5-HT5 receptor and its binding affinity for a 5-HT1A receptor being greater by at most the factor 10 than for the 5-HT5 receptor.  
     
     
         12 . The method as claimed in  claim 11 , wherein the binding affinity of the binding partner for the 5-HT5 receptor is greater than for the 5-HT1A receptor.  
     
     
         13 . The method as claimed in  claim 11 , wherein the neuropsychiatric disorder is psychosis.  
     
     
         14 . The method as claimed in  claim 13 , wherein the psychosis is selected from the group consisting of psychoses of the acute exogenous reaction type or concomitant psychoses of organic or exogenous cause, endogenous psychoses, affective disorders, and mixed forms of said psychoses.  
     
     
         15 . The method as claimed in  claim 14 , wherein the endogenous psychosis is selected from the group consisting of schizophrenia, and schizotypic and delusional disorders.  
     
     
         16 . The method as claimed in  claim 14 , wherein the affective disorder is selected from the group consisting of depression, mania and manic depressive conditions.  
     
     
         17 . The method as claimed in  claim 11 , wherein the neuropsychiatric disorder is schizophrenia.  
     
     
         18 . The method as claimed in  claim 11 , wherein the neuropsychiatric disorder is chronic schizophrenia.  
     
     
         19 . The method as claimed in  claim 11 , wherein the neuropsychiatric disorder is epilepsy.  
     
     
         20 . The method as claimed in  claim 11 , wherein the neuropsychiatric disorder is dementia.  
     
     
         21 . The method as claimed in  claim 20 , wherein the dementia is senile dementia.  
     
     
         22 . The method as claimed in  claim 20 , wherein the dementia is Alzheimer dementia.  
     
     
         23 . A method for treating signs, symptoms and/or dysfunctions of neuropsychiatric disorders, which comprises administering to a subject in need thereof an effective amount of at least one binding partner for a 5-HT5 receptor, the Ki value of the binding partner being less than 10 −7  M for binding thereof to the 5-HT5 receptor and its binding affinity for a 5-HT1A receptor being greater by at most the factor 10 than for the 5-HT5 receptor.  
     
     
         24 . The method as claimed in  claim 23 , wherein the sign, symptom and/or dysfunction is an emotional disturbance.  
     
     
         25 . The method as claimed in  claim 24 , wherein the emotional disturbance is depression.  
     
     
         26 . The method as claimed in  claim 24 , wherein the emotional disturbance is anxiety.  
     
     
         27 . The method as claimed in  claim 26 , wherein the anxiety is a symptom of schizophrenia.  
     
     
         28 . The method as claimed in  claim 23 , wherein the sign, symptom and/or dysfunction is selected from the group consisting of syllabication, euphoria, lack of facial expression, monotonous speech, depression, apathy, labile affectibility, rigid affectibility, impaired spontaneity, impaired resoluteness, slowed thinking and poor association ability.  
     
     
         29 . The method as claimed in  claim 28 , wherein the slowed thinking is a symptom of schizophrenia.